Top US health official backed a medication policy shift that benefited a company she has stock in

Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in a company providing access to menopause treatments. Ethics experts called her endorsement an “obvious conflict of interest.”

Moms, Pizzamakers to Gov Hochul: Kick Cancer Out of Our Food, Sign Food Safety Reform NOW!

FDA moves on peptides put consumers in harm's way

FDA's recent move to consider adding unproven peptides to the 503A Bulks List threatens public health, advisory committee integrity, and the drug approval process.

Four red flags and one truth amid the peptide hype

Experimental peptides are often sold at longevity, wellness, and “performance medicine” clinics — even though they haven’t proved safe and effective in clinical trials.

Non-UPF labels: Useful new tool or cause for confusion?

New labels assure you that the product you’re buying is not an ultraprocessed food. But what does that even mean?

How food companies sneak new ingredients past the FDA

The FDA's review of new food ingredients has a big legal loophole—and food and supplement companies are taking advantage of it at the expense of public health.

Letter to FDA RE: Meeting of the Pharmacy Compounding Advisory Committee on Peptides

"We are writing with concern about the recent meeting of the Pharmacy Compounding Advisory Committee (PCAC or Advisory Committee), held on July 23-24, 2026, at which the Advisory Committee, in a series of close votes, chose to recommend six of seven peptides under consideration for inclusion on the 503A bulk drug substance compounding list (503A Bulks List). Not only do those substances pose a risk to public health and safety, but the Advisory Committee’s convening and vote, if followed by a corresponding rulemaking, violates established FDA criteria for listing new substances and is substantively and procedurally defective. "For years, the Agency has exercised appropriate caution with respect to these seven peptides. In September 2023, based on the available evidence (or lack thereof), the Agency issued an interim restriction placing these substances in Category 2, a designation for “Bulk Drug Substances that Raise Significant Safety Concerns.” This continues to be the view of expert Agency staff, who, in briefing materials made available to PCAC’s members, recommended against the listing of all seven peptides considered." View the resource below to keep reading.

New FDA rule makes it easier for companies to cut sodium

Gov. Newsom blocks teen access to harmful supplements

California's new law stops the sale of weight loss or muscle-building pills to teens without a doctor's prescription.

Uninspected meat recall: What you need to know

167,639 pounds of pork, beef, and goat meat from Star Meat Delivery Inc. was recalled in September 2026. Here's what you need to know.